Galapagos Nv (GLPG)

$27

-0.02

(-0.07%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Galapagos Nv

  • Increasing Revenue

    Revenue is up for the last 2 quarters, -209.12M → 62.43M (in $), with an average increase of 435.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 157.55M → 90.22M (in $), with an average decrease of 42.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 77.4% return, outperforming this stock by 112.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 226.8% return, outperforming this stock by 285.8%

Performance

  • $27.00
    $27.38
    $27.00
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.39%

    Upside

    1.39%

    downward going graph
  • $24.78
    $44.25
    $27.00
    downward going graph

    8.22%

    Downside

    52 Weeks Volatility :44.0%

    Upside

    38.98%

    downward going graph

Returns

PeriodGalapagos NvSector (Health Care)Index (Russel 2000)
3 Months
-9.4%
6.7%
0.0%
6 Months
-30.45%
5.5%
0.0%
1 Year
-35.39%
12.6%
0.0%
3 Years
-58.97%
15.2%
-19.7%

Highlights

Market Capitalization
1.8B
Book Value
$43.93
Earnings Per Share (EPS)
0.51
PE Ratio
52.92
PEG Ratio
0.0
Wall Street Target Price
40.61
Profit Margin
114.42%
Operating Margin TTM
-53.07%
Return On Assets TTM
-1.38%
Return On Equity TTM
1.13%
Revenue TTM
243.6M
Revenue Per Share TTM
0.19
Quarterly Revenue Growth YOY
6.6000000000000005%
Gross Profit TTM
4.8M
EBITDA
-74.6M
Diluted Eps TTM
0.51
Quarterly Earnings Growth YOY
2.91
EPS Estimate Current Year
-0.25
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Hold
    38%Buy
    61%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Galapagos Nv(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
11
11
10
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 50.41%

Current $27.00
Target $40.61

Company Financials

FY18Y/Y Change
Revenue
330.4M
↑ 127.27%
Net Income
-33.5M
↓ 74.71%
Net Profit Margin
-10.13%
↑ 80.91%
FY19Y/Y Change
Revenue
946.6M
↑ 192.55%
Net Income
167.9M
↓ 612.13%
Net Profit Margin
17.73%
↑ 27.86%
FY20Y/Y Change
Revenue
588.0M
↓ 43.42%
Net Income
-382.5M
↓ 307.55%
Net Profit Margin
-65.06%
↓ 82.79%
FY21Y/Y Change
Revenue
549.1M
↑ 1.42%
Net Income
-142.0M
↓ 59.67%
Net Profit Margin
-25.87%
↑ 39.19%
FY22Y/Y Change
Revenue
541.3M
↑ 4.21%
Net Income
-233.5M
↑ 73.81%
Net Profit Margin
-43.14%
↓ 17.27%
FY23Y/Y Change
Revenue
239.7M
↓ 52.56%
Net Income
211.7M
↓ 197.11%
Net Profit Margin
88.31%
↑ 131.45%
Q4 FY22Q/Q Change
Revenue
101.9M
↓ 30.16%
Net Income
-222.0M
↓ 1061.34%
Net Profit Margin
-217.84%
↓ 233.66%
Q1 FY23Q/Q Change
Revenue
195.1M
↑ 88.04%
Net Income
25.3M
↓ 111.2%
Net Profit Margin
12.97%
↑ 230.81%
Q2 FY23Q/Q Change
Revenue
163.6M
↓ 16.17%
Net Income
5.6M
↓ 78.02%
Net Profit Margin
3.4%
↓ 9.57%
Q3 FY23Q/Q Change
Revenue
120.0M
↓ 19.96%
Net Income
25.8M
↑ 406.37%
Net Profit Margin
21.52%
↑ 18.12%
Q4 FY23Q/Q Change
Revenue
-209.1M
↓ 274.23%
Net Income
157.6M
↑ 509.98%
Net Profit Margin
-75.34%
↓ 96.86%
Q1 FY24Q/Q Change
Revenue
67.4M
↓ 129.85%
Net Income
97.4M
↓ 42.74%
Net Profit Margin
144.51%
↑ 219.85%
FY18Y/Y Change
Total Assets
1.6B
↑ 11.91%
Total Liabilities
257.7M
↓ 17.88%
FY19Y/Y Change
Total Assets
6.8B
↑ 321.58%
Total Liabilities
3.6B
↑ 1317.53%
FY20Y/Y Change
Total Assets
7.0B
↓ 5.78%
Total Liabilities
3.7B
↓ 4.56%
FY21Y/Y Change
Total Assets
5.9B
↓ 9.17%
Total Liabilities
2.9B
↓ 16.33%
FY22Y/Y Change
Total Assets
5.1B
↓ 8.83%
Total Liabilities
2.4B
↓ 13.39%
FY23Y/Y Change
Total Assets
4.4B
↓ 7.96%
Total Liabilities
1.6B
↓ 29.28%
Q4 FY22Q/Q Change
Total Assets
5.1B
↓ 4.78%
Total Liabilities
2.4B
↓ 3.22%
Q1 FY23Q/Q Change
Total Assets
5.1B
↓ 2.16%
Total Liabilities
2.3B
↓ 6.37%
Q2 FY23Q/Q Change
Total Assets
4.9B
↓ 2.37%
Total Liabilities
2.1B
↓ 6.25%
Q3 FY23Q/Q Change
Total Assets
4.5B
↓ 1.57%
Total Liabilities
1.8B
↓ 5.6%
Q4 FY23Q/Q Change
Total Assets
4.4B
↓ 2.11%
Total Liabilities
1.6B
↓ 14.64%
Q1 FY24Q/Q Change
Total Assets
4.7B
↑ 0.09%
Total Liabilities
1.6B
↓ 6.11%
FY18Y/Y Change
Operating Cash Flow
-163.0M
↓ 3.1%
Investing Cash Flow
-18.2M
↑ 2798.72%
Financing Cash Flow
329.3M
↓ 18.53%
FY19Y/Y Change
Operating Cash Flow
3.6B
↓ 2352.2%
Investing Cash Flow
-4.2B
↑ 23556.28%
Financing Cash Flow
1.5B
↑ 364.0%
FY20Y/Y Change
Operating Cash Flow
-525.6M
↓ 113.32%
Investing Cash Flow
931.5M
↓ 120.12%
Financing Cash Flow
27.1M
↓ 98.35%
FY21Y/Y Change
Operating Cash Flow
-570.6M
↑ 17.9%
Investing Cash Flow
613.0M
↓ 28.53%
Financing Cash Flow
-4.4M
↓ 117.59%
FY22Y/Y Change
Operating Cash Flow
-536.2M
↓ 0.65%
Investing Cash Flow
-1.3B
↓ 330.12%
Financing Cash Flow
-1.6M
↓ 61.64%
Q4 FY22Q/Q Change
Operating Cash Flow
-192.7M
↑ 53.8%
Investing Cash Flow
19.4M
↓ 109.92%
Financing Cash Flow
-2.1M
↓ 341.99%
Q1 FY23Q/Q Change
Operating Cash Flow
-103.5M
↓ 47.26%
Investing Cash Flow
199.1M
↑ 907.88%
Financing Cash Flow
-207.2K
↓ 90.1%
Q2 FY23Q/Q Change
Operating Cash Flow
-136.8M
↑ 32.2%
Investing Cash Flow
199.2M
↑ 0.0%
Financing Cash Flow
-1.7M
↑ 716.32%
Q3 FY23Q/Q Change
Operating Cash Flow
-118.8M
↓ 5.26%
Investing Cash Flow
182.5M
↑ 0.0%
Financing Cash Flow
-2.1M
↑ 33.4%

Technicals Summary

Sell

Neutral

Buy

Galapagos Nv is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Galapagos Nv
Galapagos Nv
6.13%
-30.45%
-35.39%
-58.97%
-84.19%
Moderna, Inc.
Moderna, Inc.
-13.26%
18.89%
0.09%
-50.76%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
6.13%
17.36%
53.1%
89.32%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
-0.29%
33.6%
77.44%
226.85%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.67%
11.71%
38.56%
146.98%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Galapagos Nv
Galapagos Nv
52.92
52.92
0.0
-0.25
0.01
-0.01
NA
43.93
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Galapagos Nv
Galapagos Nv
Hold
$1.8B
-84.19%
52.92
114.42%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Institutional Holdings

  • EcoR1 Capital, LLC

    8.74%
  • FMR Inc

    6.33%
  • Bvf Inc

    2.83%
  • Deerfield Management Co

    2.14%
  • Prosight Management, LP

    1.41%
  • Segall Bryant & Hamill

    1.32%

Company Information

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Organization
Galapagos Nv
Employees
1123
CEO
Dr. Paulus A. Stoffels M.D., Ph.D.
Industry
Health Technology

FAQs